secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALLURION TECHNOLOGIES, INC. (ALUR)
CIK:        0001964979
Form:       8-K
Filed at:   2024-09-04T23:59:59+00:00
Accession:  0000950170-24-103546
Event type: leadership
Sentiment:  positive
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allurion appoints Eli Lilly veteran Keith Johns to Board of Directors
---------------------------------------------------------------------

- Keith Johns appointed as Class III director effective Sept 2, 2024; board expands from 7 to 8 members.
- Johns spent 25 years at Eli Lilly, most recently leading Global Marketing and Alliance Management for Diabetes and Obesity.
- His expertise includes GLP-1 drug launches and obesity market strategy.
- Compensation will follow standard non-employee director policy as described in prior SEC filings.
- Johns also serves as COO of Adipo Therapeutics, focusing on brown adipose tissue obesity treatments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1964979/000095017024103546/0000950170-24-103546-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1964979/000095017024103546/alur-20240902.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-103546

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer